January 2019 Volume 15, Issue 1
Volume 15, Issue 1 | January 2019
January 2019
In this Issue
Research & Development
Scripps researchers unlock heart disease key
9p21.3 haplotype identified as a major player in cardiovascular disease riskEast meets West in new therapeutics quest
Partners launch multitarget development alliance worth up to $310MAn updated portfolio for uniQure
Gene therapy company showcases new therapies and its gene silencing platformCount Me In seeks to speed progress against cancer
A new model of patient-partnered research is at the core of recently launched nonprofit organizationPreclinical
Spray away tumors?
Gel developed at UCLA could help body fight off cancer after surgeryA new twist on immunotherapy
Research team reports on a method for altering B cells to create a new anticancer weaponA link between sugar and cancer
U.K.-based researchers find that mannose can impede tumorsNexien collaboration to focus on preclinical cannabinoid studies
Partnership will investigate advanced parenteral formulations for acute treatment of convulsive disordersALG.APV-527 activates and enhances T cells and NK cells
Alligator Bioscience and Aptevo Therapeutics presented on potential therapeutic at SITC annual meetingBusiness & Government Policy
Paying out for PARP
GSK acquires TESARO—and its PARP inhibitor Zejula—for $5.1 billionChina-bound for Merus and Promega
A license deal and innovation designation, respectively, give both companies a toe in Chinese pharma watersOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsMyoKardia and Sanofi part ways in collaboration
MyoKardia regains global rights to mavacamten and MYK-491 programsA ray of hope in patenting “products of nature” perhaps?
In a recent decision by the Federal Circuit, Roche Molecular Inc. v. Cepheid, the court raised for the first time a question regarding whether it may have over-interpreted the scope of the Supreme Court’s proscription regarding patenting compositions arising from products produced in nature in AMP v. Myriad GeneticsSpecial Reports
Special Report on Microbiomics: Army of One
Finding alliances between microbes and immune cellsCommentary
Market insight: AI and causal machine learning are accelerating discovery and more
The power of causal machine learning allows us to apply sophisticated algorithms directly to massive and complex data and accelerate the discovery of cause-and-effect relationshipsOut of order: Removing blinders
We may try to separate the mind from the rest of the body in science a lot of the time, but it turns out the microbiome might extend there as wellEditor's Focus
Editor’s focus: A ‘Q’ for ‘quality’ in Q1?
Let's take a look at the special features in store for you at DDNews in the first quarter of 2019Feature
SLAS 2019 Show Preview: A capital time for collaboration in the SLAS community
Washington, D.C., welcomes 2019’s annual meeting of the Society for Laboratory Automation and ScreeningDiscovery
Lilly, Dicerna to embark on RNAi research collaboration
Companies will focus on gene-silencing targets in the areas of cardio-metabolic disease, neurodegeneration and painGoing after glioblastoma
1ST Biotherapeutics and twoXAR Form co-development collaboration to discover and develop new brain cancer treatmentsA technology to predict biochemical reactions
Fujitsu platform could help clarify the mechanisms of genetic disorders and advance drug discoveryClinical Trials
Relieving rhinitis
ASIT begins confirmatory trial of grass pollen allergy injectionNeurocrine reevaluates Tourette program
Valbenazine fails to meet the primary endpoint in Phase 2b trial in pediatric patientsBreakthrough: WP1066 inhibits PD-L1 as well as STAT3
Moleculin’s drug, which recently began a trial for aggressive brain tumors, counteracts resistance to checkpoint blockadesVerrica announces positive top-line results from Phase 3 trials of VP-102
CAMP-1 and CAMP-2 trials for molluscum contagiosum both achieve statistical significance for the primary endpoint with p-values less than 0.0001Diagnostics
Progentec Diagnostics brings in LupusCorner
New funding brings lupus-detection tools closer to commercialization; acquisition of LupusCorner marks another step forwardCollaboration speeds access to cancer drugs
QIAGEN and NeoGenomics seek to explore potential of changes in FDA’s approach to advanced diagnostics and NGS testsNanoscale technique set to springboard cancer discoveries
University of Manchester researchers able to get more data from blood of cancer patients than previously possibleNewly published data support PancraGEN
Peer-reviewed journal article highlights important role of Interpace Diagnostics’ test for pancreatic cystsContract Services
PPD expands lab capabilities in Athlone
Company enhances gene and cell therapy lab services in Europe and North AmericaAdmescope launches new services
Company looks to serve growing biologics marketNew PDAC research
Findings published in Journal of Visualized Experiments
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
The unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
Automating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
